RT Journal Article
SR Electronic
T1 Effectiveness and Safety of Albuterol Solutions with and without Benzalkonium Chloride
JF Respiratory Care
FD American Association for Respiratory Care
SP respcare.10747
DO 10.4187/respcare.10747
A1 Awni M. Al-Subu
A1 Eric Friestrom
A1 Erica Terry
A1 Miranda R Langkamp
A1 Carolyn K. Adams
A1 Rhonda A. Yngsdal-Krenz
A1 Michael R Lasarev
A1 Ryan L DeSanti
A1 Joshua P Vanderloo
A1 Monica C. Bogenschutz
YR 2023
UL http://rc.rcjournal.com/content/early/2023/01/20/respcare.10747.abstract
AB Introduction: Continuous aerosolized β2-agonist, namely albuterol, is the most commonly used therapy for critical asthma. Benzalkonium chloride is a preservative present in some formulations of aerosolized albuterol solutions that can induce bronchospasm by itself. Recent studies have shown that inhalation of albuterol containing benzalkonium chloride might induce unintended bronchoconstriction and poor outcomes. This study aims to investigate whether using albuterol solutions containing benzalkonium chloride results in prolonged hospital length of stay (LOS).Methods: A retrospective cohort study of pediatric subjects admitted to the PICU and treated with continuous albuterol. Data was collected and compared before and after a change to benzalkonium chloride-containing solutions. Subjects who were treated with preservative-free solutions were used as control. The primary outcome was PICU and hospital LOS; secondary outcomes included the duration of continuous albuterol and use of adjunctive therapies.Results: A total of 266 admissions were included in the study. One hundred forty subjects (52.6%) were exposed to benzalkonium chloride. Median age and severity of illness scoring were similar between groups. The initial dose of continuous albuterol was significantly higher in the benzalkonium chloride group median 15 (IQR: 10–20) mg/hr compared to the preservative free group 10 (IQR: 10–20) mg/hr (p<0.001). PICU LOS was longer for the preservative -free group 2.5 (IQR: 1.4, 4.6) days vs. 1.8 (IQR: 1.1, 2.9) days for benzalkonium chloride group (p=0.002). There was no significant difference in duration of continuous albuterol therapy (p = 0.16) or need for adjunctive respiratory support [Heliox (p=0.32), NIPPV(p=0.81), and invasive mechanical ventilation (p=0.57)].Conclusions: In contrast to published literature showing that benzalkonium chloride may be associated with a longer duration of continuous albuterol nebulization and hospital LOS, our study demonstrated that benzalkonium chloride-containing albuterol is safe for continuous nebulization in critically ill children and not associated with worse outcomes.